Brincidofovir

Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo[1][2][3][4].

Product Specifications

CAS Number

[444805-28-1]

Product Name Alternative

CMX001; HDP-CDV

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

CMV; HSV; Orthopoxvirus

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/CMX001.html

Purity

99.46

Solubility

0.1 M NaOH : 50 mg/mL (ultrasonic) |DMSO : 1 mg/mL (adjust pH to 8 with NaOH; heat to 50°C)

Smiles

NC1=NC(N(C[C@@H](CO)OCP(O)(OCCCOCCCCCCCCCCCCCCCC)=O)C=C1)=O

Molecular Formula

C27H52N3O7P

Molecular Weight

561.69

Precautions

H302, H315, H319

References & Citations

[1]Hiwarkar P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129 (14) :2033-2037.|[2]Detweiler CJ, et al. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. J Pediatr Hematol Oncol. 2018;40 (6) :e364-e368.|[3]Zaitseva M, McCullough KT, Cruz S, et al. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J Virol. 2015;89 (6) :3295-3307.|[4]Scott A Foster , et al. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak. Viruses. 2017 Oct 30;9 (11) :320.